November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Find out more about the emerging field of glycobiology, which could potentially lead to a new type of cancer immunotherapy.

In 2024, startups saw a notable resurgence in large-scale funding rounds. By May, over 100 startups had secured funding ...

Discover key challenges in clinical trial design and learn how the right software can significantly boost the likelihood of ...

Discover how the emerging field of using CAR-T cell therapy to treat lupus could offer a potential cure for the autoimmune ...

Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight ...

Research in idiopathic pulmonary fibrosis is progressing rapidly, with the goal of delivering more treatments to patients at ...

The companies Metsera, Alentis Therapeutics, and Adcendo bagged the biggest private biotech investments in November 2024.

Discover how Trump’s healthcare picks could reshape U.S. biopharma and drive major changes in the healthcare policy.

Discover various promising treatments in development to address the unmet needs of people with Charcot–Marie–Tooth disease.

Discover five biosimilar companies creating affordable versions of blockbuster drugs and hoping to capitalize on the upcoming ...

Learn about process intensification in biopharma, key strategies for success, and solutions to overcome manufacturing ...